Maynard Um
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $13 at Benchmark on OLC Rejection
-
-
-
-
-
-
-
B.Riley Starts Unicycive Therapeutics (UNCY) at Buy
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $22 at H.C. Wainwright
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) regains NASDAQ compliance after reverse split
-
-
-
-
-
-
-
Lucid Capital Markets Starts Unicycive Therapeutics (UNCY) at Buy
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
-
466,310 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


